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Introduction
============

Melanoma is the first malignancy in which immunotherapy (IT) has gained widespread use in the metastatic setting. Immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and anti-programmed cell death-1 (PD-1) antibodies, which are now considered first-line therapies in patients with metastatic melanoma, can reverse the immunosuppressive effects exerted by cancer cells and promote antitumor immunity \[[@REF1]-[@REF4]\]. Despite therapeutic advances with IT, patient outcomes can still be improved as responses tend to be limited to a subset of patients who have preexisting T-cell responses that can be reactivated by immune checkpoint blockade \[[@REF5]\].

Nearly half of all patients with metastatic melanoma receive radiotherapy (RT) during their treatment, typically in the setting of oligometastases or for palliation of brain metastases, spinal cord compression, or bleeding tumors. RT has been demonstrated to induce immune-modulation through a variety of mechanisms, including increased presentation of antigens, the release of pro-inflammatory cytokines and molecules, upregulation of death receptors and ligands, and neoantigen formation \[[@REF6]\]. These immunogenic effects in turn lead to the activation of adaptive antitumor immunity. Thus, the combination of RT with immune checkpoint blockade is a promising therapeutic strategy and has led to the development of clinical trials assessing this combination.

To date, several prospective clinical trials have demonstrated the feasibility, safety, and efficacy of combining IT with RT \[[@REF7]-[@REF11]\]. Recent patterns-of-care studies have also revealed the increasing use of RT and IT in patients with metastatic melanoma \[[@REF12],[@REF13]\]. However, there is no study available to assess the effect of RT dose-fractionation and timing on overall survival (OS) outcomes of combination therapy. To address this gap in the existing literature, we used the National Cancer Database (NCDB) data on metastatic melanoma to further study the interaction between IT and RT. The primary endpoint of this study was to assess whether the use of IT with hypofractionated RT (HFRT) or conventionally fractionated RT (CFRT) in patients with metastatic melanoma was associated with OS. We also examined the effect of RT treatment site and IT timing on OS. Our hypothesis was that the use of HFRT improves OS compared to CFRT in metastatic melanoma patients receiving IT.

Materials and methods
=====================

Patient population

The NCDB is a national, hospital-based registry sponsored by the American College of Surgeons Commission on Cancer (CoC) and the American Cancer Society. It collects information on approximately 70% of all new invasive cancers diagnosed in the United States annually \[[@REF14]\]. Each year, the NCDB receives reports of over one million cancer cases from around 1,500 hospital-based programs accredited by the CoC \[[@REF14]\]. The database comprises demographic information, individual diagnosis, and treatment information such as clinical stage, RT dose and volume, and use of IT \[[@REF15]\]. The NCDB undergoes extensive internal quality monitoring and validity reviews annually \[[@REF16]\]. While the NCDB does not specify the biological agent used for each patient, IT use may include immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or anti-PD-L1), interleukins, and oncolytic virus (talimogene laherparepvec), but not BRAF (i.e., dabrafenib or vemurafenib) or MEK (i.e., trametinib) inhibitors.

A total of 19,294 patients diagnosed with stage IV melanoma between 2004-2015 were represented in the database. We excluded patients not receiving RT (n=12,205) or with incomplete or unreliable treatment information (e.g., missing total dose, fraction number, or treatment site) (n=1,174). We classified 5,915 patients who received RT with complete treatment information into CFRT (\<5 Gy/fraction) and HFRT (≥5 Gy/fraction) dose-fractionation groups (Figure [1](#FIG1){ref-type="fig"}). For CFRT, we included 3,900 patients who received total doses of RT between 20-70 Gy and ≥1.5 Gy/fraction. For HFRT, we included 1,381 patients who received total doses of RT between 15.01-70 Gy and ≤34 Gy/fraction, or 10-15 Gy in one fraction. We excluded 634 patients who did not meet the above dose criteria. CFRT and HFRT patients were further divided based on whether they had received IT or not, ultimately resulting in four treatment groups in all (CFRT+IT, CFRT alone, HFRT+IT, and HFRT alone).

![CONSORT diagram detailing patient selection\
NCDB: National Cancer Database; RT: radiotherapy; CFRT: conventionally fractionated radiotherapy; HFRT: hypofractionated radiotherapy; fx: fraction; IT: immunotherapy](cureus-0012-00000008767-i01){#FIG1}

Most patients who received CFRT were treated at 2-3 Gy/fraction, with a median dose of 30 Gy \[interquartile range (IQR): 7.50\], and the frequency and total dose distribution at each dose-per-fraction interval are shown in Figure [2A](#FIG2){ref-type="fig"}, [2B](#FIG2){ref-type="fig"}. For patients who received HFRT, the median dose was 24 Gy (IQR: 10), and the frequency and total dose distribution are shown in Figure [2C](#FIG2){ref-type="fig"}, [2D](#FIG2){ref-type="fig"}.

![Radiotherapy characteristics of the patient cohort\
Histograms depict the frequency of patients who received CFRT (A) and HFRT (C) at various dose-per-fraction intervals. Range and distribution of total RT dose are depicted using whisker-box plots for each dose-per-fraction interval in patients who received CFRT (B) and HFRT (D). Dose-per-fraction intervals on the x-axis are inclusive of the smaller value, but not the larger value \[e.g., in (A), 1,558 CFRT patients received RT between 2.00-2.99 Gy/fraction\]. A whisker-box plot consists of a lower box (yellow, 1st quartile -- median), an upper box (blue, median -- 3rd quartile), and whiskers (minimum and maximum)\
CFRT: conventionally fractionated radiotherapy; HFRT: hypofractionated radiotherapy; fx: fraction](cureus-0012-00000008767-i02){#FIG2}

Statistical analysis

Frequencies and proportions were calculated for all demographic and clinical categorical variables. Chi-square and Kruskal-Wallis tests were used to compare proportions and medians. IQRs were calculated to describe median dispersion. Statistical significance was determined at an alpha level of 0.05. Kaplan-Meier survival curves and log-rank statistics were used to examine OS. Survival estimates and 95% CIs were calculated from survival functions at three years. Survival was calculated from the date of diagnosis to the date of the last contact or confirmed death. Cox proportional hazards regression was used to examine the unadjusted hazard ratio (HR) and adjusted hazard ratios (aHR).

Patient variables included in the multivariable Cox regression model were age, sex, Charlson comorbidity score (CCS), education attainment, median household income, type of health insurance, hospital type, chemotherapy use, any type of surgery, and RT treatment sites \[brain, bone, and soft tissue/visceral (STV)\].

In a sensitivity analysis, we used one-to-one propensity-score matching (PSM) by modeling individual logistic regressions using treatment groups as dependent variable \[HFRT-IT group vs. each of the other three treatment groups (HFRT alone, CFRT-IT, and CFRT alone)\] with independent variables including age, sex, race, CCS, type of health insurance, and RT treatment site. Cox proportional hazards regression and Kaplan-Meier survival curves were used to examine survival between matched groups. All statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC).

Results
=======

Descriptive statistics

Our analysis examined 5,281 patients with stage IV melanoma who met the inclusion criteria (Figure [1](#FIG1){ref-type="fig"}). Of those, 7.3% of patients received HFRT+IT, 18.8% received HFRT alone, 11.8% received CFRT+IT, and 62.0% received CFRT alone. The mean age was 62.1 years (range: 19-90 years). Overall, most of the study population was Caucasian (97.0%), had no comorbidities (CCS: 0) (77.9%), with a higher proportion of males (69.9%), and relatively equal distribution of treatments across age groups (Table [1](#TAB1){ref-type="table"}). Patients in the HFRT+IT group had slightly fewer comorbidities (CCS: \>0) (p=0.0014) and were more likely to be treated at academic centers (p\<0.0001) and to have private insurance (p\<0.0001) than those in other treatment groups. Patients who did not receive IT were more likely to receive chemotherapy compared to those who received IT (HFRT/CFRT alone: 25.3% vs HFRT/CFRT+IT: 10.0%; p\<0.0001).

###### Demographic and clinical characteristics of stage IV melanoma patients (n=5,281) in the NCDB 2004-2015

†Proportion of the number of adults in the patient\'s zip code who did not graduate from high school

RT: radiotherapy; IT: immunotherapy; HFRT: hypofractionated radiotherapy; CFRT: conventionally fractionated radiotherapy; CCS: Charlson/Deyo comorbidity score; STV: soft tissue/visceral; NCDB: National Cancer Database

  ---------------------------------------- ------------------------ ------------------------ --------------------- -----------------------
  Patient characteristics                  HFRT+IT (N=386), n (%)   CFRT+IT (N=624), n (%)   HFRT (N=995), n (%)   CFRT (N=3,276), n (%)
  Age (years)                                                                                                       
  ≤50                                      85 (22)                  157 (25)                 195 (20)              676 (21)
  \>50-60                                  106 (27)                 159 (25)                 217 (22)              770 (24)
  \>60-70                                  93 (24)                  173 (28)                 261 (26)              794 (24)
  \>70                                     102 (26)                 135 (22)                 322 (32)              1036 (32)
  Sex                                                                                                               
  Female                                   119 (31)                 201 (32)                 279 (28)              988 (30)
  Male                                     267 (69)                 423 (68)                 716 (72)              2288 (70)
  Race                                                                                                              
  White                                    377 (98)                 608 (98)                 957 (96)              3182 (97)
  Black                                    3 (0.8)                  7 (1)                    12 (1)                48 (1)
  Native American                          0 (0)                    2 (0.3)                  1 (0.1)               3 (0.1)
  Asian                                    1 (0.3)                  0 (0)                    8 (0.8)               16 (0.5)
  Other                                    2 (0.5)                  5 (0.8)                  6 (0.6)               10 (0.3)
  Hispanic ethnicity                                                                                                
  No                                       370 (96)                 593 (95)                 931 (94)              3030 (92)
  Yes                                      9 (2)                    15 (2)                   18 (2)                71 (2)
  CCS                                                                                                               
  0                                        320 (83)                 507 (81)                 798 (80)              2491 (76)
  1                                        51 (13)                  77 (12)                  132 (13)              534 (16)
  2                                        15 (4)                   40 (6)                   65 (7)                251 (8)
  Income 2008-12, (\$)                                                                                              
  ≥62,000                                  167 (43)                 230 (37)                 359 (36)              1000 (31)
  ≥47,999-62,999                           119 (31)                 195 (31)                 261 (26)              923 (28)
  ≥38,000-47,999                           73 (19)                  119 (19)                 219 (22)              818 (25)
  \<38,000                                 25 (6)                   75 (12)                  140 (14)              465 (14)
  Education attainment^†^                                                                                           
  \<7%                                     138 (36)                 190 (30)                 294 (30)              789 (24)
  7-12.9%                                  145 (38)                 204 (33)                 318 (32)              1126 (34)
  13-20.9%                                 74 (19)                  163 (26)                 244 (25)              855 (26)
  \>21%                                    27 (7)                   62 (10)                  125 (13)              438 (13)
  Insurance                                                                                                         
  Private insurance                        208 (54)                 308 (49)                 427 (43)              1263 (39)
  Not insured                              13 (3)                   33 (5)                   36 (4)                188 (6)
  Medicaid                                 20 (5)                   47 (8)                   70 (7)                331 (10)
  Medicare                                 139 (36)                 209 (33)                 422 (42)              1378 (42)
  Other government                         3 (0.8)                  18 (3)                   21 (2)                71 (2)
  Hospital type                                                                                                     
  Academic/research cancer program         199 (52)                 236 (38)                 470 (47)              1029 (31)
  Community cancer program                 7 (2)                    46 (7)                   28 (3)                302 (9)
  Comprehensive community cancer program   95 (25)                  232 (37)                 283 (28)              1405 (43)
  Integrated network cancer program        49 (13)                  55 (9)                   152 (15)              325 (10)
  Chemotherapy                                                                                                      
  No                                       351 (91)                 556 (89)                 722 (72)              2448 (75)
  Yes                                      35 (9)                   66 (11)                  268 (27)              814 (25)
  Any type of surgery                                                                                               
  No                                       303 (78)                 508 (81)                 778 (78)              2678 (82)
  Yes                                      83 (22)                  116 (19)                 216 (22)              592 (18)
  RT treatment site                                                                                                 
  Brain                                    273 (71)                 323 (52)                 689 (69)              2102 (64)
  Bone                                     33 (9)                   119 (19)                 62 (6)                467 (14)
  STV sites                                80 (21)                  182 (29)                 244 (25)              707 (22)
  ---------------------------------------- ------------------------ ------------------------ --------------------- -----------------------

Survival analysis

In univariate models, most patient characteristics were significantly associated with the risk of dying, except for race, income, and chemotherapy use (Table [2](#TAB2){ref-type="table"}). On multivariate analysis, age of \>60 years (aHR range: 1.20-1.60), male sex (aHR: 1.11, 95% CI: 1.03-1.20; p=0.0061), and CCS of ≥1 (aHR range: 1.19-1.22) were associated with increased risk of death. Patients who were not insured (aHR: 1.28, 95% CI: 1.09-1.51; p=0.0029) or on Medicaid (aHR: 1.32, 95% CI: 1.16-1.51; p\<0.0001) had higher risk of dying compared to patients on private insurance. However, the most significant factor associated with the risk of dying on multivariate analysis was the type of treatment received. Patients who received CFRT alone (aHR: 2.81, 95% CI: 2.36-3.34; p\<0.0001), CFRT+IT (aHR: 1.95, 95% CI: 1.59-2.39; p\<0.0001), and HFRT alone (HR: 1.57, 95% CI: 1.31-1.89; p\<0.0001) were all at higher risk of dying compared to patients treated with HFRT+IT.

###### Univariate and multivariate Cox regression analysis of individual demographic and clinical characteristics with overall survival in the population receiving RT (n=5,281)

†Proportion of the number of adults in the patient\'s zip code who did not graduate from high school

RT: radiotherapy; IT: immunotherapy; HFRT: hypofractionated radiotherapy; CFRT: conventionally fractionated radiotherapy; CCS: Charlson/Deyo comorbidity score; STV: soft tissue/visceral; REF: reference; HR: hazard ratio; CI: confidence interval

  ---------------------------------------- ------------------------ ---------- -------------------------- ----------
  Patient characteristics                  Univariate HR (95% CI)   P-value    Multivariate HR (95% CI)   P-value
  Type of treatment                                                                                        
  HFRT+IT                                  REF                                 REF                         
  CFRT+IT                                  1.73 (1.44-2.09)         \<0.0001   1.95 (1.59-2.39)           \<0.0001
  HFRT alone                               1.68 (1.42-2.00)         \<0.0001   1.57 (1.31-1.89)           \<0.0001
  CFRT alone                               2.87 (2.45-3.36)         \<0.0001   2.81 (2.36-3.34)           \<0.0001
  Age (years)                                                                                              
  ≤50                                      REF                                 REF                         
  \>50-60                                  1.09 (0.99-1.20)         0.0824     1.08 (0.96-1.20)           0.2000
  \>60-70                                  1.19 (1.09-1.31)         0.0002     1.20 (1.06-1.35)           0.0035
  \>70                                     1.53 (1.40-1.67)         \<0.0001   1.60 (1.40-1.82)           \<0.0001
  Sex                                                                                                      
  Female                                   REF                                                             
  Male                                     1.15 (1.08-1.24)         \<0.0001   1.11 (1.03-1.20)           0.0061
  Race                                                                                                     
  White                                    REF                                 REF                         
  Black                                    1.02 (0.78-1.34)         0.8761     \-                         \-
  Native American                          0.96 (0.40-2.30)         0.9238     \-                         \-
  Asian                                    0.69 (0.40-1.19)         0.1792     \-                         \-
  Other                                    0.93 (0.58-1.50)         0.7635     \-                         \-
  Hispanic ethnicity                                                                                       
  No                                       REF                                 REF                         
  Yes                                      0.76 (0.61-0.95)         0.0168     0.84 (0.65-1.08)           0.1737
  CCS                                                                                                      
  0                                        REF                                 REF                         
  1                                        1.24 (1.13-1.35)         \<0.0001   1.19 (1.08-1.30)           0.0003
  2                                        1.43 (1.27-1.62)         \<0.0001   1.22 (1.07-1.39)           0.0036
  Income 2008-12, (\$)                                                                                     
  ≥62,000                                  REF                                 REF                         
  ≥47,999-62,999                           1.05 (0.97-1.14)         0.2498     \-                         \-
  ≥38,000-47,999                           1.05 (0.96-1.14)         0.2775     \-                         \-
  \<38,000                                 1.07 (0.96-1.18)         0.2223     \-                         \-
  Education attainment^†^                                                                                  
  \<7%                                     REF                                 REF                         
  7-12.9%                                  1.10 (1.01-1.19)         0.0244     1.03 (0.92-1.16)           0.6182
  13-20.9%                                 1.01 (0.93-1.11)         0.7887     0.94 (0.86-1.04)           0.2104
  \>21%                                    1.07 (0.96-1.19)         0.2008     1.07 (0.98-1.17)           0.1347
  Insurance                                                                                                
  Private insurance                        REF                                 REF                         
  Not insured                              1.25 (1.09-1.45)         0.0021     1.28 (1.09-1.51)           0.0029
  Medicaid                                 1.27 (1.13-1.42)         \<0.0001   1.32 (1.16-1.51)           \<0.0001
  Medicare                                 1.38 (1.29-1.48)         \<0.0001   1.07 (0.97-1.18)           0.1950
  Other government                         1.04 (0.83-1.30)         0.7265     0.88 (0.68-1.12)           0.2935
  Hospital type                                                                                            
  Academic/research cancer program         REF                                 REF                         
  Community cancer program                 1.50 (1.33-1.70)         \<0.0001   1.24 (1.08-1.42)           0.0018
  Comprehensive community cancer program   1.33 (1.23-1.43)         \<0.0001   1.16 (1.07-1.25)           0.0003
  Integrated network cancer program        1.21 (1.09-1.35)         0.0004     1.14 (1.02-1.28)           0.0254
  Chemotherapy                                                                                             
  No                                       REF                                 REF                         
  Yes                                      1.02 (0.95-1.10)         0.5776     \-                         \-
  Any type of surgery                                                                                      
  No                                       REF                                 REF                         
  Yes                                      0.72 (0.66-0.78)         \<0.0001   0.82 (0.75-0.89)           \<0.0001
  RT treatment site                                                                                        
  STV sites                                REF                                 REF                         
  Brain                                    1.58 (1.46-1.71)         \<0.0001   1.75 (1.60-1.91)           \<0.0001
  Bone                                     1.57 (1.41-1.76)         \<0.0001   1.52 (1.35-1.72)           \<0.0001
  ---------------------------------------- ------------------------ ---------- -------------------------- ----------

The median follow-up time for the cohort was 5.9 (IQR: 11.4) months. Overall, HFRT+IT patients had the highest three-year OS \[37.3% (95% CI: 31.1-43.5)\] compared to HFRT alone \[19.0% (95% CI: 16.2-21.9)\], CFRT+IT \[17.6% (95% CI: 13.9-21.6)\], and CFRT alone \[8.6% (95% CI: 7.6-9.7), overall log rank: \<0.0001\] (Figure [3](#FIG3){ref-type="fig"}). HFRT+IT group had a significantly higher three-year OS compared to the CFRT+IT group (p\<0.0001). Compared to RT-alone patients, the addition of IT was associated with improved three-year OS in both HFRT (HFRT alone vs. HFRT+IT, p\<0.0001) and CFRT (CFRT alone vs. CFRT+IT, p\<0.0001) treatment groups. However, the magnitude of OS benefit associated with IT was significantly larger in the HFRT group (three-year ΔOSIT=18.3%) compared to the CFRT group (three-year ΔOSIT=9.0%, p\<0.0001) (Figure [3](#FIG3){ref-type="fig"}).

![Kaplan-Meier curves for overall survival for entire cohort\
The entire cohort was stratified by treatment received\
HFRT: hypofractionated radiotherapy; CFRT: conventionally fractionated radiotherapy; IT: immunotherapy; OS: overall survival](cureus-0012-00000008767-i03){#FIG3}

Stratification by RT treatment site (Figures [4](#FIG4){ref-type="fig"}-[6](#FIG6){ref-type="fig"}) showed that the survival benefit of HFRT+IT was evident for brain and STV metastatic sites. For patients treated for metastatic brain sites, three-year OS was highest for HFRT+IT \[34.6% (95% CI: 27.1-42.3)\] compared to HFRT alone \[18.4% (95% CI: 15.2-21.9)\], CFRT+IT \[12.5% (95% CI: 8.0-18.0)\], or CFRT alone \[5.6% (95% CI: 4.6-6.8)\] (Figure [4](#FIG4){ref-type="fig"}). For those treated for metastatic STV sites, three-year OS was also highest for HFRT+IT \[45.9% (95% CI: 33.1-57.8)\] compared to HFRT alone \[19.0% (95% CI: 13.7-25.1)\], CFRT+IT \[24.8% (95% CI: 17.8-32.4)\], or CFRT alone \[18.8% (95% CI: 15.7-22.1)\] (Figure [5](#FIG5){ref-type="fig"}). The OS benefit with the addition of IT was significantly greater in the HFRT group compared to the CFRT group for patients who received RT to the brain (three-year ΔOSIT: HFRT vs CFRT, 16.2% vs 6.9%, p\<0.0001) or STV sites (three-year ΔOSIT: HFRT vs CFRT, 26.9% vs 6.0%, p\<0.0001) sites. On the other hand, while treatment with HFRT+IT in patients who received RT to bone sites was associated with the highest OS, the addition of IT to HFRT did not significantly improve survival (Figure [6](#FIG6){ref-type="fig"}).

![Overall survival of patients who received RT to the brain\
The subset of patients who received radiotherapy to the brain was stratified by treatment received\
HFRT: hypofractionated radiotherapy; CFRT: conventionally fractionated radiotherapy; IT: immunotherapy; OS: overall survival](cureus-0012-00000008767-i04){#FIG4}

![Overall survival of patients who received RT to STV sites\
The subset of patients who received radiotherapy to STV sites was stratified by treatment received\
HFRT: hypofractionated radiotherapy; CFRT: conventionally fractionated radiotherapy; IT: immunotherapy; STV: soft tissue/visceral; OS: overall survival](cureus-0012-00000008767-i05){#FIG5}

![Overall survival of patients who received RT to the bone\
The subset of patients who received radiotherapy to the bone was stratified by treatment received\
HFRT: hypofractionated radiotherapy; CFRT: conventionally fractionated radiotherapy; IT: immunotherapy; OS: overall survival](cureus-0012-00000008767-i06){#FIG6}

After PSM, 1,200 patients (n=300 per treatment group) were available for analysis (Table [3](#TAB3){ref-type="table"}). Treatment with HFRT+IT continued to be associated with superior three-year OS \[36.6% (95% CI: 30.0-43.5)\] compared to HFRT alone \[20.4% (95% CI: 15.4-25.9)\], CFRT+IT \[16.0% (95% CI: 10.9-21.9)\], and CFRT alone \[6.5% (95% CI: 3.9-10.0)\]. OS benefit associated with the utility of IT remained significantly greater in the HFRT group (three-year ΔOSIT=16.2%) compared with the CFRT group (three-year ΔOSIT=9.5%, p\<0.0001) (Figure [7](#FIG7){ref-type="fig"} and Table [4](#TAB4){ref-type="table"}).

###### Propensity-score-matched population for stage IV melanoma patients (n=1,200) in the NCDB 2004-2015

RT: radiotherapy; IT: immunotherapy; HFRT: hypofractionated radiotherapy; CFRT: conventionally fractionated radiotherapy; CCS: Charlson/Deyo comorbidity score; STV: soft tissue/visceral; NCDB: National Cancer Database

  ------------------------- ---------------- ---------------- ------------------- -------------------
  Patient characteristics   HFRT+IT, n (%)   CFRT+IT, n (%)   HFRT alone, n (%)   CFRT alone, n (%)
  Age (years)                                                                      
  ≤50                       70 (23)          70 (23)          70 (23)             68 (23)
  \>50-60                   82 (27)          82 (27)          82 (27)             84 (27)
  \>60-70                   76 (25)          76 (25)          76 (25)             76 (25)
  \>70                      72 (24)          72 (24)          72 (24)             72 (24)
  Sex                                                                              
  Female                    84 (28)          84 (28)          84 (28)             81 (27)
  Male                      216 (72)         216 (72)         216 (72)            219 (73)
  Race                                                                             
  White                     299 (100)        299 (100)        299 (100)           299 (100)
  Others                    1 (0)            1 (0)            1 (0)               1 (0)
  CCS                                                                              
  0                         10 (3)           10 (3)           10 (3)              10 (3)
  1                         29 (10)          29 (10)          29 (10)             29 (10)
  2                         261 (87)         261 (87)         261 (87)            261 (87)
  Insurance                                                                        
  Private insurance         176 (59)         176 (59)         176 (59)            176 (59)
  Not insured               5 (2)            5 (2)            5 (2)               5 (2)
  Medicaid                  10 (3)           10 (3)           10 (3)              10 (3)
  Medicare                  108 (36)         108 (36)         108 (36)            108 (36)
  Other government          1 (0.3)          1 (0.3)          1 (0.3)             1 (0.3)
  Site treated                                                                     
  Brain                     218 (72)         218 (72)         218 (72)            218 (72)
  Bone                      24 (8)           24 (8)           24 (8)              24 (8)
  STV sites                 58 (19)          58 (19)          58 (19)             58 (19)
  ------------------------- ---------------- ---------------- ------------------- -------------------

![Overall survival after propensity-score matching of 1,200 patients (n=300 for each treatment group)\
HFRT: hypofractionated radiotherapy; CFRT: conventionally fractionated radiotherapy; IT: immunotherapy; OS: overall survival](cureus-0012-00000008767-i07){#FIG7}

###### Univariate Cox regression analysis for propensity-score-matched population

RT: radiotherapy; IT: immunotherapy; HFRT: hypofractionated radiotherapy; CFRT: conventionally fractionated radiotherapy; REF: reference; HR: hazard ratio; CI: confidence interval

  ------------------------- ------------------------ ---------
  Patient characteristics   Univariate HR (95% CI)   P-value
  Type of treatment                                   
  HFRT+IT                   REF                       
  CFRT+IT                   1.86 (1.48-2.33)         \<0.01
  HFRT alone                1.57 (1.26-1.96)         \<0.01
  CFRT alone                2.96 (2.39-3.66)         \<0.01
  ------------------------- ------------------------ ---------

Of patients treated with both RT and IT, survival was similar regardless of IT timing \[neoadjuvant IT (IT \>30 days prior to RT), concurrent IT (IT within 30 days of RT) or adjuvant IT (IT \>30 days after RT)\] (Figure [8](#FIG8){ref-type="fig"}). After stratification by site treated, patients who received treatment to the brain showed a difference in survival that was marginally significant in favor of concurrent/adjuvant IT (log rank: 0.0749) (Figure [9](#FIG9){ref-type="fig"}). Conversely, survival was similar in patients who received treatment to STV sites or bone when stratified by IT timing (Figures [10](#FIG10){ref-type="fig"}, [11](#FIG11){ref-type="fig"}).

![Subset analysis of IT timing on overall survival\
Patients who received both RT and IT (n=1,010) were stratified by the timing of initiating IT relative to RT\
RT: radiotherapy; IT: immunotherapy](cureus-0012-00000008767-i08){#FIG8}

![Effect of IT timing on overall survival in patients who received RT to the brain\
Patients who received RT to the brain and IT (n=596) were stratified by IT timing\
RT: radiotherapy; IT: immunotherapy](cureus-0012-00000008767-i09){#FIG9}

![Effect of IT timing on overall survival in patients who received RT to STV sites\
Patients who received RT to STV sites and IT (n=262) were stratified by IT timing\
RT: radiotherapy; IT: immunotherapy; STV: soft tissue/visceral](cureus-0012-00000008767-i10){#FIG10}

![Effect of IT timing on overall survival in patients who received RT to the bone\
Patients who received RT to the bone and IT (n=152) were stratified by IT timing\
RT: radiotherapy; IT: immunotherapy](cureus-0012-00000008767-i11){#FIG11}

Discussion
==========

For patients receiving IT for metastatic melanoma, RT treatment with HFRT was associated with superior survival compared to CFRT. Moreover, patients treated with HFRT was associated with significantly greater survival benefit from the use of IT compared to those treated with CFRT, especially patients treated with RT to the brain and STV sites. We obtained similar findings after PSM analysis, including matching by irradiated sites.

Currently, there is no evidence to guide the optimal dose-fractionation of RT in combination with IT for the treatment of any malignancy. There are only a handful of ongoing clinical trials evaluating RT fraction size in combination with IT \[[@REF17]\]. However, available clinical evidence has shown that RT with higher dose-per-fraction, when combined with IT, results in favorable outcomes in metastatic melanoma. Several studies have reported evidence of the abscopal effect with stereotactic body RT (SBRT) in metastatic melanoma patients receiving IT \[[@REF18]-[@REF20]\]. Moreover, in a recent systemic review of studies reporting the therapeutic efficacy of combined RT and ipilimumab in metastatic melanoma, patients who received higher doses-per-fraction (\>3 Gy) showed better clinical outcomes \[[@REF21]\]. Similarly, preclinical evidence skews toward HFRT/SBRT fraction sizes to be more effective in providing therapeutic synergy with IT \[[@REF17]\].

In this study, we showed that metastatic melanoma patients who received IT had significantly higher OS if they received HFRT (\>5 Gy/fraction) rather than CFRT (≤5 Gy/fraction). Moreover, we further ascertained the survival contribution of IT in patients receiving palliative RT by comparing patients treated with HFRT or CFRT, with or without IT. Although patients receiving either CFRT or HFRT were associated with significant improvement in three-year OS when IT was also given compared to their counterparts who did not receive IT, the absolute survival benefit from IT in patients receiving HFRT was greater than those receiving CFRT. As such, our analyses suggest that there is a differential effect with different RT dose-fractionations, with the combination of HFRT and IT potentially exhibiting greater therapeutic effect that translates into improved survival. One possible reason for this observation of ours is that patients who were treated with CFRT for palliation may potentially benefit less from IT. Greater number of RT fractions and a generally larger area of treatment with CFRT may lead to more substantial lymphopenia, which can hinder tumor cell eradication by cytotoxic T lymphocytes \[[@REF22]-[@REF24]\]. Another possibility is that patients receiving HFRT may benefit more from IT, perhaps due to the synergistic effects of higher dose-per-fraction with checkpoint inhibition, as previously discussed \[[@REF17]-[@REF20]\].

The treatment site is likely an important determinant of the response to therapy. It has been suggested that RT to lungs and liver is more immunogenic than to other organs \[[@REF25],[@REF26]\]. Furthermore, although brain parenchyma was previously considered to be immune-privileged, recent evidence has shown that immune cells can cross the blood-brain barrier, and brain metastases from melanoma respond to immune checkpoint inhibitors \[[@REF27]-[@REF29]\]. Consistent with this, our analysis demonstrated that patients with metastatic brain or STV lesions demonstrated a greater survival benefit with the addition of IT to HFRT compared to those with osseous metastatic lesions.

There are several limitations to this study. First, differential misclassification may still exist toward HFRT being a more effective treatment than CFRT against metastatic melanoma using the NCDB database. For example, patients treated with radiosurgery may have had an intracranial disease of lower volume than those who received whole-brain RT; similarly, patients treated with CFRT to the bones were more likely to harbor diffuse osseous metastases than those who underwent SBRT. Additionally, CFRT may be less effective in eradicating melanoma cells, which are less radiosensitive with a lower α/β ratio \[[@REF30]\]. Finally, HFRT dosing can often achieve a higher biologically effective dose to the tumor lesions and result in greater tumoricidal effect. To circumvent these biases, we minimized the potential for misclassification by comparing HFRT or CFRT patients who received IT with their respective counterparts who did not. As such, we were able to determine the benefit derived from IT in HFRT or CFRT patients separately, rather than directly comparing HFRT patients with CFRT patients. Second, this is a retrospective study that utilized data collected only from facilities accredited by the CoC, which may generally include patients who received higher quality care and had better outcomes. Third, while we adjusted our models for important covariates, we were unable to account for factors that were not available in the database, including total disease burden, size and number of lesions treated by RT, or the type of immunotherapeutic agents utilized. Finally, we were unable to exclude the possibility that patients may have received multiple courses of RT to the same or different disease sites.

Despite these limitations, our study has several strengths. In addition to defining the two dose-fractionation criteria by a commonly-used threshold of 5 Gy/fraction, we only included patients who received clinically meaningful doses of RT at any given dose-per-fraction to ensure that we captured the appropriate cohort for our analysis. Furthermore, we examined the survival differences imparted by IT by including HFRT-/CFRT-alone groups in our four-arm analysis. Additionally, our results after PSM were very similar to that of the original analysis, indicating that selection bias had a minimal effect on our analysis.

Conclusions
===========

Our analysis demonstrated that patients treated with IT in combination with higher dose-per-fraction using HFRT had superior OS compared to those treated with IT and CFRT. Furthermore, we observed a differential effect of IT on RT fractionation, with significantly greater improvement in OS when IT was utilized in patients treated with HFRT compared to CFRT, especially in patients who received RT to the brain and STV sites. Altogether, we believe our study contributes to the literature by addressing a critical gap of knowledge regarding the optimal dose-fractionation of palliative RT for metastatic melanoma in conjunction with IT, thereby underscoring the significance of and providing potential guidance for future prospective studies addressing this issue. Furthermore, designing trials by utilizing specific immunotherapeutic agents is essential to better evaluate the interactive effects with RT.
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